Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

us' press releases are available at http://www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Forward-Looking Statements

This Press release contains and the accompanying conference call will contain "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Examples of such statements include: (i) statements regarding the goals, progress and expected timing of clinical studies, including the progress, timing and design of Phase 3 clinical development for Amigal, the progress and timing of the availability of data from the Phase 2 extension study of Amigal, the progress and timing of Phase 2 clinical trials for Plicera for the treatment of Gaucher disease, the timing of the release of data from the Phase 2 clinical trials for Plicera, the initiation of Phase 2 clinical development of AT2220 for the treatment of Pompe disease, and the possibility and timin
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 A study has been launched to ... 1 track could help to tackle the problem of obesity. ... (a GP surgery based in Stowmarket) and academics at University ... Telemetry technology, which is inspired by equipment used to ...
(Date:1/15/2014)... January 15, 2014 2013 was a ... Brain State Technologies®. They saw continued independent research led ... who were awarded a $1 million grant from the ... “Brain and Behavior” a peer reviewed journal, Amy Grant ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... Jan. 14, 2014 The largest international professional ... plants and therapeutic derivatives thereof has endorsed an ... researchers about the challenges of adulterated herb and ... The Society for Medicinal Plant ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8
... June 13, 2011 K-V Pharmaceutical Company (the "Company") (NYSE: ... for the fiscal year ended March 31, 2011 with the ... be holding an investor conference call today at 4:30 p.m. ... a general update on other company matters. Participants can listen ...
... 2011 Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTICD and MTA: ... list of preliminary additions to the Russell 3000® Index and ... 2011 at www.russell.com .  Russell Investments will finalize the ... on June 24, 2011. "We are very ...
... 10, 2011 /PRNewswire-Asia-FirstCall/ -- China Cord Blood Corporation (NYSE: ... of cord blood collection, laboratory testing, hematopoietic stem cell processing, ... results for the fourth quarter and fiscal year of 2011, ... Quarter of Fiscal 2011 Highlights Revenue in ...
Cached Biology Technology:K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 2K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 3K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 4K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 5K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 6K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call 7Cell Therapeutics on Preliminary List of Additions to Russell 3000® Index and Russell Global Index 2Cell Therapeutics on Preliminary List of Additions to Russell 3000® Index and Russell Global Index 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 2China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 3China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 4China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 5China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 6China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 7China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 8China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 9China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011 10
(Date:4/22/2014)... not only on weight loss but also on diabetes ... University of Cincinnati have shown that the health benefits ... size but by increased levels of bile acids in ... indicate that bile acids could be a new target ... the Sahlgrenska Academy has demonstrated that obesity surgery is ...
(Date:4/21/2014)... 2014 Performing brain research that can one day ... Houston (UH) junior Khanh (Kate) Nguyen has been recognized ... double major in mathematics and physics, Nguyen is among ... , One of the most prestigious awards available ... sophomore and junior students majoring in mathematics, the natural ...
(Date:4/21/2014)... predict which drug candidates offer the greatest potential has ... drug-like molecules and the amino acids of proteins vary ... cunningly managed to develop a method that has proven ... class of human target proteins for drugs are the ... per cent of all drugs on the market. These ...
Breaking Biology News(10 mins):Researchers identify a mechanism linking bariatric surgery to health benefits 2UH student named Goldwater Scholar, 2 more receive honorable mention 2UH student named Goldwater Scholar, 2 more receive honorable mention 3UH student named Goldwater Scholar, 2 more receive honorable mention 4Simulating in tiny steps gave birth to long-sought-after method 2
... Gent - VIB/UGent researchers have unveiled a mechanism that can ... For years, improving drought tolerance has been a major aim ... extreme drought stress. However, translating this research to the field ... in Nature Biotechnology and the Plant Cell ...
... the brain that uses hearing to determine sound location is ... a new study by a team of researchers from Virginia ... These findings propose a new theory for cross-modal plasticity: ... maintaining the original function of the brain region. ...
... Richmond, Va. (May 10, 2011) Cancer researchers ... for advanced prostate cancer after effectively combining an ... vivo using novel ultrasound-targeted microbubble-destruction (UTMD) technology. The ... University Massey Cancer Center, VCU Institute of Molecular ...
Cached Biology News:Drought tolerance in crops: Shutting down the plant's growth inhibition under mild stress 2For hearing parts of brain, deafness reorganizes sensory inputs, not behavioral function 2Microbubble-delivered combination therapy eradicates prostate cancer in vivo 2
... between the various commercial and lab-prepared glass ... the length and GC content of the ... protocol employed all influence the optimal hybridization ... all the different variables to consider, it ...
... Gel Stain combo offers these benefits: ... separately Offers a safer ... Eliminates risks to yourself, the environment and ... 100 bp to >30 kb. UltraPure Agarose is a ...
This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
... 400 unique human proteins on a ... proteins, all extracellular proteins (EP) according ... in quadruplicate for high-quality results. Additional ... layout guarantee high validity and reproducibility., ...
Biology Products: